Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Olaparib in Patients With BRCA Mutated Platinum-Sensitive Relapsed Serous Ovarian Cancer: New Data Presented at ASCO
Olaparib in Patients With BRCA Mutated Platinum-Sensitive Relapsed Serous Ovarian Cancer: New Data Presented at ASCO
Olaparib in Patients With BRCA Mutated Platinum-Sensitive Relapsed Serous Ovarian Cancer: New Data Presented at ASCO
Submitted by
admin
on June 1, 2013 - 12:25pm
Source:
Yahoo/BusinessWire
News Tags:
olaparib
ovarian cancer
AstraZeneca
Headline:
Olaparib in Patients With BRCA Mutated Platinum-Sensitive Relapsed Serous Ovarian Cancer: New Data Presented at ASCO
Do Not Allow Advertisers to Use My Personal information
